.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,736,561

« Back to Dashboard

Details for Patent: 5,736,561

Title: Vascular hypertrophy suppressor
Abstract:This invention relates to a method for the prophylaxis or treatment of vascular hypertropy in a mammal by administering a pharmaceutically effective amount of a compound represented by the formula (I): ##STR1## wherein ring W is a nitrogen-containing heterocyclic ring residue which may be substituted; R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which optionally binds through a hetero-atom; R.sup.3 represents a group capable of forming an anion or a group capable of changing thereto; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic length of two or less; n denotes 1 or 2; a and b forming the heterocyclic ring residue are independently one or two optionally substituted carbon or hetero atoms; c is an optionally substituted carbon or hetero atom; provided that, when the ring W is a condensed ring, R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which binds through a hetero atom, or a salt thereof to a mammal in need thereof.
Inventor(s): Nishikawa; Kohei (Kyoto, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Filing Date:Jan 18, 1996
Application Number:08/588,240
Claims:1. A method for the prophylaxis or treatment of vascular hypertrophy in a mammal by administering thereto a pharmaceutically effective amount of a compound of the following formula (I), or a salt thereof: ##STR23## wherein: A is a substituted or unsubstituted benzene ring having the substituent R.sup.2 ;

R.sup.1 is alkyl, alkenyl, alkynyl or cycloalkyl which binds through a group of the formula: --N(R.sup.9)-- wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S().sub.m -- wherein m is an integer of 0 to 2 and which may be substituted with hydroxy, optionally substituted amino, halogen, lower (C.sub.1-4) alkoxy or lower (C.sub.1-4) alkylthio; or

R.sup.1 is aryl or aralkyl which may bind through a group of the formula: --N(R.sup.9)-- wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m -- wherein m is an integer of 0 to 2 and which may be substituted with halogen, nitro, optionally substituted amino, lower (C.sub.1-4) alkoxy, lower (C.sub.1-4) alkylthio or lower (C.sub.1-4) alkyl;

R.sup.2 is optionally esterified or amidated carboxyl, tetrazolyl, trifluoromethanesulfonic amide, phosphoric acid or sulfonic acid, which may be protected with optionally substituted lower alkyl or acyl;

R.sup.3 is one of the following: ##STR24## and n is 1 or 2.

2. The method of claim 1 wherein R.sup.1 is lower (C.sub.1-8) alkyl, lower (C.sub.2-8) alkenyl or lower (C.sub.3-6) cycloalkyl which binds through a group of the formula: --N(R.sup.9)-- wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m -- wherein m is an integer of 0 to 2 and which may be substituted with hydroxy, amino, N-lower (C.sub.1-4) alkylamino, N,N-dilower (C.sub.1-4) alkylamino, halogen, lower (C.sub.1-4) alkoxy or lower (C.sub.1-4) alkylthio.

3. The method of claim 1 wherein R.sup.1 is alkyl or alkenyl which binds through a group of the formula: --N(R.sup.9)-- wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m-- wherein m is an integer of 0 to 2 and which may be substituted with hydroxy, optionally substituted amino, halogen, lower (C.sub.1-4) alkoxy or lower (C.sub.1-4) alkylthio.

4. The method of claim 1 wherein R.sup.2 is a group of the formula: --CO--D wherein D is hydroxy, optionally substituted amino or optionally substituted alkoxy.

5. The method of claim 4 wherein the optionally substituted alkoxy is lower (C.sub.1-6) alkoxy whose alkyl moiety may be substituted with hydroxy, optionally substituted amino, halogen, lower (C.sub.1-6) alkoxy, lower (C.sub.1-6) alkylthio or optionally substituted dioxolenyl, or a group of the formula: --O--CH(R.sup.4)--OCOR.sup.5 wherein R.sup.4 is hydrogen, lower (C.sub.1-6) alkyl, lower (C.sub.2-6) alkenyl or lower (C.sub.3-8) cycloalkyl; and R.sup.5 is lower (C.sub.1-6) alkyl, lower (C.sub.2-6) alkenyl, lower (C.sub.3-8) cycloalkyl, lower (C.sub.1-3) alkyl substituted with lower (C.sub.3-8) cycloalkyl or aryl, lower (C.sub.2-3) alkenyl optionally substituted with lower (C.sub.3-8) cycloalkyl or aryl, aryl, lower (C.sub.1-6) alkoxy, lower (C.sub.2-8) alkenyloxy, lower (C.sub.3-8) cycloalkyloxy, lower (C.sub.1-3) alkoxy substituted with lower (C.sub.3-8) cycloalkyl or aryl, lower (C.sub.2-3) alkenyloxy substituted with lower (C.sub.3-8) cycloalkyl or aryl, or aryloxy.

6. The method of claim 1 wherein R.sup.2 is optionally esterified carboxy.

7. The method of claim 1 wherein n is 1.

8. The method of claim 1 wherein said compound of formula (I) is 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylic acid.

9. The method of claim 1 wherein said compound of formula (I) is pivaloyloxymethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylate.

10. The method of claim 1 wherein said compound of formula (I) is 2-ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]meth yl]-1H-benzimidazole-7-carboxylic.

11. The method of claim 1 wherein said vascular hypertrophy occurs after percutaneous transluminal coronary angioplasty.

12. The method of claim 1 wherein said vascular hypertrophy occurs after bypass surgery.

13. The method of claim 1 wherein said vascular hypertrophy occurs due to arteriosclerosis.

14. The method of claim 1 wherein the method is a method of treatment of vascular hypertrophy.

15. The method of claim 8 wherein the method is method of treatment of vascular hypertrophy.

16. The method of claim 10 wherein the method is a method of treatment of vascular hypertrophy.

17. The method of claim 4 wherein the method is a method of treatment of vascular hypertrophy.

18. The method of claim 11 wherein said compound is 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylic acid or a pharmaceutically acceptable salt thereof.

19. The method of claim 1 wherein said compound 2-ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]meth yl]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof.

20. The method of claim 12 wherein said compound is 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl ]methyl]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof.

21. The method of claim 12 wherein said compound is 2-ethoxy-1-[[2'(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methy l]-1H-benzimidazole-7-carboxylic acid or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc